脱氧核糖核酸（DNA）疫苗市场（2026—2031）
脱氧核糖核酸（DNA）疫苗市场规模预计由2026年的5.8174亿美元增至2031年的8.2292亿美元，预测期复合年增长率为7.18%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
脱氧核糖核酸（DNA）疫苗市场规模预计由2026年的5.8174亿美元增至2031年的8.2292亿美元，预测期复合年增长率为7.18%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 7.18% | 机构预测 |
| 市场规模 | 2026 | USD 581.74 million | 机构预测 |
| 市场规模 | 2031 | USD 822.92 million | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| delivery_method | electroporation | 2025 | 55.630% |
| end_user | hospitals and clinics | 2025 | 61.320% |
| indication | infectious diseases | 2025 | 38.630% |
| route_of_administration | intradermal delivery | 2025 | 48.630% |
| technology_platform | plasmid DNA | 2025 | 72.160% |
| type | human DNA vaccines | 2025 | 61.830% |
| vaccine_purpose | prophylactic vaccines | 2025 | 65.380% |
关键结论
- delivery_method 维度中，electroporation 在 2025 年的公开份额为 55.63%。
- end_user 维度中，hospitals and clinics 在 2025 年的公开份额为 61.32%。
- indication 维度中，infectious diseases 在 2025 年的公开份额为 38.63%。
- route_of_administration 维度中，intradermal delivery 在 2025 年的公开份额为 48.63%。
- technology_platform 维度中，plasmid DNA 在 2025 年的公开份额为 72.16%。
- type 维度中，human DNA vaccines 在 2025 年的公开份额为 61.83%。
主要参与者
- Boehringer Ingelheim Animal Health USA Inc.
- Eurogentec S.A.
- Takara Bio Inc.
- Touchlight Genetics Ltd.
- Zoetis Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Faster Response to Emerging and Re-emerging Pathogens | +1.100% | Global, with early demand in Sub-Saharan Africa, Southeast Asia, and the Middle East | Short term (≤ 2 years) |
| Growing Therapeutic Oncology and Personalized Vaccine Pipelines | +1.800% | North America and Europe, with later trial expansion in Asia-Pacific | Medium term (2-4 years) |
| Greater Demand for Stable, Scalable Vaccine Platforms | +1.300% | Global, with strong relevance in South and Southeast Asia and Sub-Saharan Africa | Medium term (2-4 years) |
| Expansion of Veterinary and Zoonotic Disease Prevention | +0.800% | North America, Europe, and Asia-Pacific | Short term (≤ 2 years) |
| Public-Private Funding for Pandemic Preparedness | +0.700% | Global, with funding centered in North America, Europe, and selected Asia-Pacific countries | Medium term (2-4 years) |
| Antigen-Design Reuse Across Variant and Pathogen Programs | +0.600% | Global | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Lower Human Immunogenicity With Conventional Injection | -0.800% | Global | Short term (≤ 2 years) |
| Electroporation-Associated Procedure Burden | -0.500% | Global, especially primary care settings outside specialist centers | Short term (≤ 2 years) |
| Limited Human Commercial Validation and Reimbursement Precedent | -0.700% | North America and Europe | Medium term (2-4 years) |
| Device-Vaccine Combination-Product CMC Complexity | -0.400% | North America and Europe | Medium term (2-4 years) |
报告关注的关键问题
What is driving DNA vaccines demand through 2031?
The category is forecast to grow at a 7.18% CAGR from 2026 to 2031, supported by stable storage, reusable plasmid designs, oncology programs, and animal health applications.
How large will DNA vaccines become by 2031?
The DNA vaccines market size is projected to reach USD 822.92 million by 2031, from USD 581.74 million in 2026.
Which DNA vaccine application is growing fastest?
Oncology is the fastest-growing indication, with a projected 9.21% CAGR through 2031, as personalized neoantigen programs advance clinically.
Why is lipid nanoparticle delivery important for DNA vaccines?
Lipid and nanoparticle delivery is projected to grow at an 8.82% CAGR because it may reduce dependence on electroporation equipment and improve practical delivery.
Which region has the highest projected growth for DNA vaccines?
Asia-Pacific is forecast to grow at an 8.76% CAGR from 2026 to 2031, supported by activity in India, China, South Korea, Japan, and Australia.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence